SAMJIN PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SAMJIN PHARMACEUTICAL CO.,LTD's Market Cap is ₩2378B. At end of 2025 it was ₩2631B. Ranked #729 of 2,436 in KR market (top 30%), #414 of 787 on KOSPI (top 53%), #81 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 237.76B KRW | KR#729/2,436 Sec#81/234 |
| Revenue | 306.35B KRW | KR#809/2,436 Sec#37/234 |
| Net Income | 21.84B KRW | KR#621/2,436 Sec#42/234 |
| Total Assets | 452.49B KRW | KR#793/2,436 Sec#49/234 |
| Net Assets | 277.59B KRW | KR#732/2,436 Sec#48/234 |
| Employees | 809 | KR#309/2,436 Sec#27/234 |
| Value | ||
| P/E | 10.89x | KR#760/2,436 Sec#41/234 |
| P/B | 0.86x | KR#1,349/2,436 Sec#83/234 |
| P/S | 0.78x | KR#1,218/2,436 Sec#64/234 |
| EV/EBITDA | 13.69x | KR#804/2,436 Sec#46/234 |
| FCF Yield | 9.45% | KR#644/2,436 Sec#28/234 |
| Profitability | ||
| ROE | 7.87% | KR#705/2,436 Sec#46/234 |
| ROA | 4.83% | KR#672/2,436 Sec#52/234 |
| Op. Margin | 8.34% | KR#596/2,436 Sec#53/234 |
| Revenue Growth | -3.93% | KR#1,653/2,436 Sec#154/234 |
| Earnings Growth | -62.56% | KR#1,257/2,436 Sec#81/234 |
| Financial Health | ||
| Debt Ratio | 63.00% | KR#214/2,436 Sec#31/234 |
| Total Debt | 119.00B KRW | KR#649/2,436 Sec#38/234 |
| FCF | 22.47B KRW | KR#484/2,436 Sec#28/234 |
| Cash | 7.14B KRW | KR#1,853/2,436 Sec#161/234 |
| Current Ratio | 1.28x | KR#1,490/2,436 Sec#158/234 |
| Net Debt/EBITDA | 4.38x | KR#1,049/2,436 Sec#80/234 |
| Dividend | ||
| Div. Yield | 4.53% | KR#344/2,436 Sec#12/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -10.30% | KR#973/2,436 Sec#71/234 |
| 1M Return | -3.15% | KR#1,227/2,436 Sec#120/234 |
| From 52W High | -31.08% | KR#438/2,436 Sec#29/234 |
| 1Y MDD | -31.13% | KR#235/2,436 Sec#15/234 |
| Trading | ||
| Volume | 29,856 shares | KR#1,653/2,436 Sec#162/234 |
| Foreign Own. | 3.46% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,594 KRW | KR#456/2,436 Sec#31/234 |
| BPS | 21,931 KRW | KR#477/2,436 Sec#33/234 |
Company Info
Samjin Pharmaceutical, established in 1968, manufactures and sells pharmaceuticals, boasting a diverse portfolio that includes Gabol tablets and Plaless tablets. The company is expanding its business into health functional foods, cosmetics, and medical devices, with a strong focus on developing new drugs for conditions such as cancer and dementia. Following the completion of an EU-GMP-grade injectable line at its Osong raw material synthesis plant in 2022, Samjin Pharmaceutical is boosting production and facility investments for global growth. Samjin Pharmaceutical is headquartered in Mapo-gu, Seoul.